Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer

Oncogene volume 25, pages 3335–3345 (2006)Cite this article

Abstract

Non-small-cell lung cancer (NSCLC) represents the most frequent and therapy-refractive sub-class of lung cancer. Improving apoptosis induction in NSCLC represents a logical way forward in treating this tumor. Cisplatin, a commonly used therapeutic agent in NSCLC, induces activation of N-terminal-c-Jun kinase (JNK) that, in turn, mediates induction of apoptosis. In analysing surgical tissue samples of NSCLC, we found that expression of MKP1/CL100, a negative regulator of JNK, showed a strong nuclear staining for tumor cells, whereas, in normal bronchial epithelia, MKP1 was localized in the cytoplasm as well as in nuclei. In the NSCLC-derived cell lines H-460 and H-23, we found that MKP1 was constitutively expressed. Expressing a small-interfering RNA (siRNA) vector for MKP1 in H-460 cells resulted in a more efficient activation by cisplatin of JNK and p38 than in the parental cells, and this correlated with a 10-fold increase in sensitivity to cisplatin. A similar response was also observed in H-460 and H-23 cells when treated with the MKP1 expression inhibitor RO-31-8220. Moreover, expression of a siRNA-MKP2, an MKP1-related phosphatase, had no effect on H-460 cell viability response to cisplatin. Tumors induced by H-460 cells expressing MKP1 siRNA grew slower in nu−/nu− mice and showed more susceptibility to cisplatin than parental cells, and resulted in an impaired growth of the tumor in mice. On the other hand, overexpression of MKP1 in the H-1299 NSCLC-derived cell line resulted in further resistance to cisplatin. Overall, the results showed that inhibition of MKP1 expression contributes to a slow down in cell growth in mice and an increase of cisplatin-induced cell death in NSCLC. As such, MKP1 can be an attractive target in sensitizing cells to cisplatin to increase the effectiveness of the drug in treating NSCLC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11

Similar content being viewed by others

References

  • Alpert D, Schwenger P, Han J, Vilcek J . (1999). J Biol Chem 274: 22176–22183.

  • Beltman J, McCormick F, Cook SJ . (1996). J Biol Chem 271: 27018–27024.

  • Bossy W, Bakiri I, Yaniv M . (1997). EMBO J 16: 1695–1709.

  • Denkert C, Schmitt WD, Berger S, Reles A, Pest S, Siegert A et al. (2002). Int J Cancer 102: 507–513.

  • Dérijard B, Hibi M, Wu I-H, Barret T, Su B, Deng T et al. (1994). Cell 76: 1025–1037.

  • Eastman A . (1985). Biochemistry 24: 5027–5032.

  • Ham J, Babij C, Whitfield J, Pfarr CM, Lallemand D, Yaniv M et al. (1995). Neuron 14: 927–939.

  • Hibi M, Lin A, Minden A, Karin M . (1993). Genes Dev 7: 2135–2148.

  • Hirsch DD, Stork PJ . (1997). J Biol Chem 272: 4568–4575.

  • Keyse SM . (1995). Biochim Biophys Acta 1265: 152–160.

  • Kim DH, Kim JS, Park JH, Ji YI, Kwon YM, Shim YM et al. (2003). Cancer Res 63: 6206–6211.

  • Kyriakis J.M, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF et al. (1994). Nature 369: 156–160.

  • Levin WJ, Casey G, Ramos JC, Arboleda MJ, Reissmann PT, Slamon DJ . (1994). Chest 106(Suppl 6): 372S–376S.

  • Li J, Gorospe M, Hutter D, Barnes J, Keyse SM, Liu Y . (2001). Mol Cell Biol 21: 8213–8224.

  • Liao Q, Guo J, Kleeff J, Zimmermann A, Buchler MW, Korc M et al. (2003). Gastroenterology 124: 1830–1845.

  • Lim EH, Aggarwal A, Agasthian T, Wong PS, Tan C, Sim E et al. (2003). Clin Cancer Res 9: 5980–5987.

  • Liu Y, Gorospe M, Yang C, Holbrook NJ . (1995). J Biol Chem 270: 8377–8380.

  • Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P et al. (1997). Lab Invest 76: 37–51.

  • Mizuno R, Oya M, Shiomi T, Marumo K, Okada Y, Murai M . (2004). J Urol 172: 723–727.

  • Perona R, Sánchez-Pérez I . (2004). Br J Cancer 90: 573–577.

  • Persons DL, Yazlovitskaya EM, Cui W, Pelling JC . (1999). Clin Cancer Res 5: 1007–1014.

  • Sánchez-Pérez I, Martinez-Gomariz M, Willians D, Keyse SM, Perona R . (2000). Oncogene 19: 5142–5152.

  • Sánchez-Pérez I, Murguia JR, Perona R . (1998). Oncogene 16: 533–541.

  • Sánchez-Pérez I, Perona R . (1999). FEBS Lett 453: 151–158.

  • Slebos RJ, Rodenhuis S . (1989). Eur Respir J 2: 461–469.

  • Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ . (2004). Mol Pharmacol 66: 1478–1490.

  • Srikanth S, Franklin CC, Duke RC, Kraft RS . (1999). Mol Cell Biochem 199: 169–178.

  • Standaert ML, Bandyopadhyay G, Antwi EK, Farese RV . (1999). Endocrinology 140: 2145–2151.

  • Vicent S, Garayoa M, Lopez-Picazo JM, Lozano MD, Toledo G, Thunnissen FB . (2004). Clin Cancer Res 10: 3639–3649.

  • Vivanco I, Sawyers SL . (2002). Nat Rev Cancer 2: 489–501.

  • Wang HY, Cheng Z, Malbon CC . (2003). Can Lett 191: 229–237.

  • Wiest JS, Franklin WA, Drabkin H, Gemmill R, Sidransky D, Anderson MW . (1997). J Cell Biochem Suppl 29: 64–73.

  • Woessmann W, Chen X, Borkhardt A . (2002). Cancer Chemother Pharmacol 50: 397–404.

  • Wu JJ, Bennett AM . 2005. J Biol Chem 280: 16461–16466.

Download references

Acknowledgements

We thank I Sanchez-Pérez for useful comments, JJ Sanchez for advice in statistics and F Nuñez and M Marsá for help with the studies in mice. We also thank S Keyse for providing MKP2 plasmid and E Diaz Lopez and V Torres for expert technical assistance. This work was supported by the following grants: no. 08.1/0048.1/2003 from the Comunidad Autónoma de Madrid; no. 01/1094, no. 02/0774 and no. 02/1094 from the Fondo de Investigación Sanitaria; no. RTICC C03/10 from Instituto de Salud Carlos III. The investigators RM-P and CM-G are supported by Grant no. RTICC C03/10.

Author information

Author notes

  1. S Chattopadhyay and R Machado-Pinilla: These authors contributed equally to this work.

Authors and Affiliations

  1. Translational Oncology Unit CSIC/UAM, Instituto de Investigaciones Biomédicas, C/Arturo Duperier, Madrid, Spain

    S Chattopadhyay, R Machado-Pinilla, C Manguan-García, C Moratilla & R Perona

  2. Servicio de Oncología Médica, Hospital La Paz, Madrid, Spain

    C Belda-Iniesta, P Cejas, J A Fresno-Vara, J de Castro-Carpeño, E Casado & M Gonzalez-Barón

  3. Servicio de Anatomía Patológica Hospital La Paz, Madrid, Spain

    M Nistal

Authors
  1. S Chattopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Machado-Pinilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Manguan-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Belda-Iniesta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Moratilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Cejas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J A Fresno-Vara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J de Castro-Carpeño
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Casado
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Nistal
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Gonzalez-Barón
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Perona
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Perona.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chattopadhyay, S., Machado-Pinilla, R., Manguan-García, C. et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 25, 3335–3345 (2006). https://doi.org/10.1038/sj.onc.1209364

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209364

Keywords

This article is cited by

Search

Advanced search

Quick links